Fusen Pharmaceutical (1652) Fundamentals 2026 — Revenue Analysis | SniperIQ

.12 on the HKSE. This SniperIQ fundamentals page covers Fusen Pharmaceutical's valuation, profitability (net margin -4.3%), revenue (¥273M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Fusen Pharmaceutical's market cap?

Fusen Pharmaceutical (1652) has a market capitalization of approximately HK$828M, trading at HK

.12 on the HKSE. Market cap moves with the live share price.

What is Fusen Pharmaceutical's P/E ratio?

Fusen Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Fusen Pharmaceutical?

Fusen Pharmaceutical runs a net profit margin of -4.3%, a gross margin of 40.2%, and an operating margin of -0.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Fusen Pharmaceutical generate?

Fusen Pharmaceutical reported revenue of ¥273M for fiscal year 2025, with net income of -¥12M and earnings per share (EPS) of -0.0159. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Fusen Pharmaceutical pay a dividend?

Fusen Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Fusen Pharmaceutical financially healthy?

Fusen Pharmaceutical carries a debt-to-equity ratio of 0.90x and a current ratio of 0.56x, with a market beta of 0.27. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Fusen Pharmaceutical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fusen Pharmaceutical (1652) the key facts are: market cap HK$828M, revenue ¥273M, 52-week range 0.3-1.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.